Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

LQDA vs AVDL: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AVDL Captures Overall Composite Edge (62.9 BUY vs 26.6 SELL), While LQDA Leads 6–0 on Growth & Valuation Pillars

AVDL Overall Winner 6-Pillar Tally: LQDA 6 – 0 AVDL Matrix Metrics: LQDA 5 – 5 AVDL

As of Nov 20, 2026, Avadel Pharmaceuticals plc Ordinary Share (AVDL) captures the overall head-to-head institutional edge over Liquidia Corporation (LQDA) on higher Unified Composite conviction (62.9/100 BUY vs. 26.6/100 SELL) after splitting the core matrix 5–5 (led by composite factor balance), while LQDA wins 6–0 across the 6-pillar growth and valuation breakdown. LQDA trades at $54.43 (15.8x Forward P/E, 47.1% operating margin) versus AVDL at $21.64 (28.8x Forward P/E, 2.5% operating margin).

  • Growth vs. Quality Trade-Off: AVDL earns the overall head-to-head edge with a stronger Unified Composite Score (62.9/100 BUY vs. LQDA 26.6/100 SELL) and 0.14β · 2% Vol risk profile, whereas LQDA leads top-line expansion (+314.6% YoY revenue growth, N/M PEG, and 6 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: LQDA is currently in a Breakdown options structure phase (RSI 59.5); meanwhile AVDL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About LQDA vs AVDL
LQDA NASDAQ
Liquidia Corporation Common Stock
Pharmaceutical Preparations
$54.43
-3.88% 1D
Market Cap $5.1B
TTM Revenue $622M
Forward P/E 15.8x
Beta / 30D Vol 0.83β · 76% Vol
Unified Composite Score
26.6 / 100 SELL
Tech 50.0 Fund 34.0 Flow 69.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 60
RSI-14: 59.5 · SMA20: $49.79 · SMA50: $47.77
AVDL NASDAQ Head-to-Head Winner
Avadel Pharmaceuticals plc Ordinary Share
Pharmaceutical Preparations
$21.64
+0.05% 1D
Market Cap $2.1B
TTM Revenue $249M
Forward P/E 28.8x
Beta / 30D Vol 0.14β · 2% Vol
Unified Composite Score
62.9 / 100 BUY
Tech 75.0 Fund 60.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.4% over 20 days), RSI 62
RSI-14: 62.3 · SMA20: $21.56 · SMA50: $21.50

6-Pillar Scorecard Institutional Category Breakdown (LQDA 6 – 0 AVDL)

Columns: Metric · LQDA · AVDL
1. Valuation Multiples LQDA
Forward P/E 15.8x 28.8x
Trailing P/E 18.2x 16.8x
PEG Ratio N/M 0.07x
EV / Revenue 7.8x 8.5x
2. Growth & Scale LQDA
Revenue Growth (YoY) +314.6% +54.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $622M $249M
Market Cap $5.1B $2.1B
3. Profitability & Quality LQDA
Gross Margin 92.7% 94.9%
Operating Margin 47.1% 2.5%
Net Profit Margin -15.2% -0.1%
Return on Equity (ROE) 131.8% -0.3%
4. Balance Sheet & Cash Flow LQDA
Cash Generation (TTM) $288M $2.7M EBITDA
Cash Flow Margin 46.3% 1.1% EBITDA Mgn
Net Cash / Leverage $227M Net Cash $1.01 Book/Sh · -0.3% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning LQDA
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 68.4% (9th %ile) 2.4% (<1st %ile)
Put/Call OI Skew 0.10x (Call-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat LQDA
OpEx & R&D Intensity 45.6% of Rev ($284M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: LQDA (5) vs AVDL (5)
Institutional Metric LQDA AVDL Criterion Row Edge
Market Capitalization
Scale
$5.1B $2.1B Larger Scale LQDA
Trailing P/E Ratio
Valuation
18.2x 16.8x Lower Multiple AVDL
Forward P/E Ratio
Valuation
15.8x 28.8x Lower Multiple LQDA
Revenue Growth (YoY)
Growth
+314.6% +54.9% Higher Growth LQDA
Operating Margin (TTM)
Profitability
47.1% 2.5% Higher Margin LQDA
Net Profit Margin
Profitability
-15.2% -0.1% Higher Margin AVDL
Return on Equity (ROE)
Capital Efficiency
131.8% -0.3% Higher ROE LQDA
52-Week Range Position
Momentum
45% ($22–$94) 89% ($6–$24) Stronger Trend AVDL
Beta / 30D Volatility
Risk Regime
0.83β · 76% Vol 0.14β · 2% Vol Lower Realized Risk AVDL
Unified Institutional Score
Composite Signal
26.6 / 100 (SELL) 62.9 / 100 (BUY) Higher Composite AVDL
Trailing 12M Revenue (USD)
Operating Scale
$622M $249M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
92.7% 94.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 7.8x EV/Rev 0.07x PEG · 8.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$288M ($227M Net Cash) $2.7M EBITDA ($1.01 Book/Sh · -0.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon LQDA +9.1 pp
LQDA: +9.75% · AVDL: +0.65%
3M Horizon LQDA +41.85 pp
LQDA: +35.53% · AVDL: -6.32%
6M Horizon LQDA +41.85 pp
LQDA: +35.53% · AVDL: -6.32%
1Y Horizon LQDA +41.85 pp
LQDA: +35.53% · AVDL: -6.32%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on LQDA vs AVDL. Trailing 12-month operating profitability (LQDA 47.1% vs AVDL 2.5%) and valuation multiples (LQDA 15.8x vs AVDL 28.8x Forward P/E) are benchmarked directly in Pillar 4 below.

LQDA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$622M
Gross Margin92.7%
Op. Margin47.1%
ROE / Fwd P/E131.8% · 15.8x
AVDL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$249M
Gross Margin94.9%
Op. Margin2.5%
ROE / Fwd P/E-0.3% · 28.8x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
LQDA BREAKDOWN
85d in phase · OBV NEUTRAL
Current IV 68.4%
IV Percentile 9th %ile
Put/Call OI Skew 0.10x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact LQDA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AVDL UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 2.4%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AVDL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $56.37 · IV 66.8%

LQDA Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($5,637)

Compare $5,637 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 66.8% ATM IV.

5-DAY BULLISH SWING Liq A

Dec 18 $55 / $65 Bull Call Spread

Buy 1x $55C · Sell 1x $65C · 32d

Net Entry $301 Debit
T+5d @ +5% Move +$99 (+33%)
Max Risk / Buffer $301 Capped
5d Edge & Liquidity 0.9x R:R · Liq A
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq C

Dec 18 $50 / $45 Bull Put Spread

Sell 2x $50P · Buy 2x $45P · 32d

Net Entry $80 Credit
Max Credit / Yield +$80 (+8.7% RoM)
Max Risk / Buffer -12.0% Cushion ($920 Mgn)
5d Edge & Liquidity 77% PoP · Liq C
Simulate 5-Day Payoff →
ASYMMETRIC 3-LEG STRUCTURE Liq C

Dec 18 $50P / $57.5-$65C Seagull

Sell 1x $50P · Buy 1x $57.5/$65C · 32d

Net Entry $207 Debit
T+5d @ +5% Move +$135 (+15.4% RoM)
Max Risk / Buffer -11.3% Put Cushion ($872 Mgn)
5d Edge & Liquidity 0.8x R:R · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
LQDA Moat Profile High-Margin Pricing Power Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $5.1B market capitalization and 47.1% operating margin.
OpEx & R&D Reinvestment 45.6% of Rev ($284M)
90D Engineering Disclosures 0 Published
AVDL Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $2.1B market capitalization and 2.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ LQDA vs AVDL Key Questions & Quantitative Answers

As of Nov 20, 2026, Avadel Pharmaceuticals plc Ordinary Share (AVDL) captures the overall head-to-head institutional edge over Liquidia Corporation (LQDA) on higher Unified Composite conviction (62.9/100 BUY vs. 26.6/100 SELL) after splitting the core matrix 5–5 (led by composite factor balance), while LQDA wins 6–0 across the 6-pillar growth and valuation breakdown. LQDA trades at $54.43 (15.8x Forward P/E, 47.1% operating margin) versus AVDL at $21.64 (28.8x Forward P/E, 2.5% operating margin). Growth vs. Quality Trade-Off: AVDL earns the overall head-to-head edge with a stronger Unified Composite Score (62.9/100 BUY vs. LQDA 26.6/100 SELL) and 0.14β · 2% Vol risk profile, whereas LQDA leads top-line expansion (+314.6% YoY revenue growth, N/M PEG, and 6 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: LQDA is currently in a Breakdown options structure phase (RSI 59.5); meanwhile AVDL trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 62.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

LQDA leads the Growth & Scale pillar: LQDA posts +314.6% YoY revenue growth and +0.0% YoY earnings growth on $622M TTM revenue (92.7% gross margin, 47.1% operating margin), compared with AVDL at +54.9% YoY revenue growth and +0.0% YoY earnings growth on $249M TTM revenue (94.9% gross margin, 2.5% operating margin). On trailing 12-month operating scale, LQDA generates $622M in USD-normalized revenue versus $249M for AVDL. In operating R&D and SG&A reinvestment, LQDA deploys 45.6% of Rev ($284M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AVDL.

LQDA screens cheaper on headline valuation multiples. LQDA trades at 15.8x Forward P/E, 18.2x Trailing P/E, N/M PEG, and 7.8x EV/Revenue (46.3% FCF margin), whereas AVDL trades at 28.8x Forward P/E, 16.8x Trailing P/E, 0.07x PEG, and 8.5x EV/Revenue (1.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LQDA (131.8% ROE) versus AVDL (-0.3% ROE) capital efficiency.

In options market volatility and institutional positioning, LQDA carries 68.4% implied volatility (9th %ile, Compressed (<25th %ile)), a 0.10x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.83β · 76% Vol realized risk). By comparison, AVDL carries 2.4% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.14β · 2% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.